» Clinical Development » Mechanism of Action: From clinical evidence to molecular understanding

Anaxomics unveils the molecular mechanisms underlying biological and clinical phenomena, including the therapeutic effect of a drug or the complex events in the pathogenesis of a disease. Our proprietary TPMS technology generates non-obvious, biologically supported hypotheses that are represented in easy-to-read graphical schemes.

Mechanism of Action: From clinical evidence to molecular understanding

Anaxomics TPMS© technology employs the latest breakthroughs in systems biology to generate mechanistic hypotheses that explain how a given stimulus drives a biological effect. These hypotheses, termed mechanism of action (MoA), link certain genes, proteins or drugs with known physiological or pathophysiological pathways based on the holistic analysis of complex biological networks.

Thanks to the biological and clinical information embedded in TPMS, our MoAs are consistent with reality, hence providing a framework for testing and validating the consequences of a stimulus on a molecular level. MoAs are visualized in the form of graphical representations where nodes are genes or proteins and lines show the relationship between them.

Mechanisms of action account for variability in nature

Anaxomics reproduces the variability of human populations by creating several plausible MoAs that conform to the existing knowledge and explain all the observed physiological responses. Thus, our virtual systems faithfully emulate what happens in nature: there are different ways to reach to the same outcome. See our White Paper for more information.

Mechanisms of action deepen your understanding

Complete understanding of safety and efficacy profile of drugs.

The FDA and EMA are emphasizing the importance of understanding the molecular and physiological basis of therapies. In connection with the new regulatory requirements, Anaxomics' TPMS suggests mechanistical explanations for the therapeutic effect of drugs.

Complete understanding of disease pathogenesis.

Failures in preclinical development reveal the potential deficiencies in our understanding of the pathogenesis of diseases and potential pitfalls in the correct choice of therapeutic targets. Loyal to our commitment towards improving human health, we help our clients to better comprehend clinical observations and put them in the context of human physiology.

moa